UNICA IRIS Institutional Research Information System

ONALI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 62.712
NA - Nord America 2.774
AS - Asia 1.309
SA - Sud America 360
AF - Africa 38
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 4
Totale 67.202
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 62.039
US - Stati Uniti d'America 2.731
SG - Singapore 689
BR - Brasile 293
CN - Cina 287
SE - Svezia 251
VN - Vietnam 160
DE - Germania 115
FI - Finlandia 94
GB - Regno Unito 59
FR - Francia 36
HK - Hong Kong 31
AR - Argentina 30
PL - Polonia 24
KR - Corea 22
IN - India 21
CA - Canada 20
BD - Bangladesh 19
MX - Messico 17
ZA - Sudafrica 16
AT - Austria 14
NL - Olanda 14
ES - Italia 12
RU - Federazione Russa 10
TR - Turchia 10
EC - Ecuador 9
ID - Indonesia 9
IQ - Iraq 9
SA - Arabia Saudita 9
IE - Irlanda 7
JP - Giappone 7
PY - Paraguay 7
UA - Ucraina 7
UZ - Uzbekistan 7
KE - Kenya 6
MA - Marocco 6
PK - Pakistan 6
CL - Cile 5
CO - Colombia 5
GR - Grecia 5
CZ - Repubblica Ceca 4
IL - Israele 4
VE - Venezuela 4
AU - Australia 3
BE - Belgio 3
CH - Svizzera 3
EG - Egitto 3
HU - Ungheria 3
IR - Iran 3
KZ - Kazakistan 3
LU - Lussemburgo 3
BG - Bulgaria 2
EU - Europa 2
GY - Guiana 2
LK - Sri Lanka 2
NZ - Nuova Zelanda 2
PE - Perù 2
PH - Filippine 2
TN - Tunisia 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
GA - Gabon 1
GT - Guatemala 1
HR - Croazia 1
JM - Giamaica 1
KG - Kirghizistan 1
LB - Libano 1
LT - Lituania 1
LV - Lettonia 1
MK - Macedonia 1
MY - Malesia 1
NI - Nicaragua 1
NP - Nepal 1
PA - Panama 1
QA - Qatar 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TG - Togo 1
Totale 67.202
Salva come PNG Salva come JPEG
Città #
Cagliari 59.996
Uta 1.921
Ashburn 508
Singapore 278
Fairfield 276
Nyköping 204
Dallas 176
Boardman 166
Seattle 117
Wilmington 115
Chandler 105
Houston 104
Woodbridge 104
Cambridge 102
Helsinki 72
Santa Clara 72
Los Angeles 67
New York 64
Beijing 60
Boston 56
Dong Ket 52
Redwood City 46
Ho Chi Minh City 40
Hefei 39
Ann Arbor 35
Rome 32
Hong Kong 31
São Paulo 30
Buffalo 29
Munich 27
Redondo Beach 25
Hangzhou 24
Seoul 22
London 21
The Dalles 21
San Diego 20
Warsaw 20
Hanoi 19
Chicago 14
Frankfurt am Main 14
Turku 14
Atlanta 13
Shanghai 13
Belo Horizonte 12
Stockholm 12
Montreal 11
Nuremberg 11
Vienna 10
Jacksonville 9
Phoenix 9
Düsseldorf 8
Elk Grove Village 8
Lappeenranta 8
Mountain View 8
Nanjing 8
Rio de Janeiro 8
Salvador 8
Haiphong 7
Mexico City 7
Tashkent 7
Tokyo 7
Brooklyn 6
Denver 6
Johannesburg 6
Orem 6
San Jose 6
Amsterdam 5
Chattanooga 5
Chennai 5
Columbus 5
Council Bluffs 5
Curitiba 5
Da Nang 5
Jiaxing 5
Manchester 5
Nairobi 5
Redmond 5
San Francisco 5
Selargius 5
Wuhan 5
Ankara 4
Brasília 4
Brno 4
Dearborn 4
Jeddah 4
Kilburn 4
Limeira 4
Milan 4
New Delhi 4
Newark 4
Norwalk 4
Piscataway 4
Poplar 4
Recife 4
Ribeirão Preto 4
São Gonçalo 4
Tianjin 4
Toronto 4
Baghdad 3
Bogotá 3
Totale 65.500
Salva come PNG Salva come JPEG
Nome #
IBD Flare in the COVID-19 Pandemic: Therapy Discontinuation Is to Blame 9.030
Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab 2.057
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 2.047
Colonic phenotype of the ileum in Crohn's disease: A prospective study before and after ileocolonic resection 1.966
Ileal lesions in patients with ulcerative colitis after ileo-rectal anastomosis: Relationship with colonic metaplasia 1.840
Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease 1.607
Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients 1.572
Response Assessed by Ultrasonography as Target of Biological Treatment for Crohn's Disease 1.546
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 1.526
The Resolution of Intestinal Inflammation: The Peace-Keeper's Perspective 1.501
Steroid-free remission and closure of recto-vaginal fistula using adalimumab in a Crohn's disease patient naïve to anti-tumour necrosis factor alpha antibodies 1.464
Cancer and immunomodulators in inflammatory bowel diseases 1.350
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease 1.305
A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease 1.292
Adalimumab in active ulcerative colitis: A "real-life" observational study 1.186
Psoriasis phenotype in inflammatory bowel disease: A case-control prospective study 1.179
Small bowel capsule endoscopy vs conventional techniques in patients with symptoms highly compatible with Crohn's Disease 1.177
Endoscopic vs ultrasonographic findings related to Crohn's Disease recurrence: A prospective longitudinal study at 3 years 1.142
Tbet Expression in Regulatory T Cells Is Required to Initiate Th1-Mediated Colitis 1.135
Anti-TNF-alpha treatments and obstructive symptoms in Crohn's Disease: A prospective study 1.101
The Italian clinical experience with adalimumab in Crohn's disease: Eleven clinical cases 1.058
A novel Smad7 genetic variant mapping on the genomic region targeted by Mongersen is associated with Crohn's disease 1.044
Female reproductive health and inflammatory bowel disease: A practice-based review 1.032
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 1.007
Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort 979
Tumor infiltrating regulatory t cells in sporadic and colitis-associated colorectal cancer: The red little riding hood and the wolf 969
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy 952
GPR120/FFAR4: A Potential New Therapeutic Target for Inflammatory Bowel Disease 906
Measuring disease activity in Crohn's disease 906
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 906
Post-operative recurrence of Crohn's disease: A prospective study at 5 years 864
Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial 864
TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in Inflammatory bowel disease 848
Long-term safety of Infliximab for the treatment of inflammatory bowel disease: Does blocking TNFα reduce colitis-associated colorectal carcinogenesis? 824
Comparative Effectiveness Research: A Roadmap to Sail the Seas of IBD Therapies 801
A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study 798
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 790
Laparoscopic versus open ileo-colonic resection in crohn's disease: Short- and long-term results from a prospective longitudinal study 789
Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology 775
Efficacy and safety of infliximab and adalimumab in Crohn's disease: A single centre study 767
Cancer in Crohn's disease patients treated with infliximab: A long-term multicenter matched pair study 763
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study 715
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 702
Development of a numerical index quantitating small bowel damage as detected by ultrasonography in Crohn's disease 685
A family study of asymptomatic small bowel Crohn's disease 678
Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study 674
Immune system and gut microbiota senescence in elderly IBD patients 669
Small intestine contrast ultrasonography vs computed tomography enteroclysis for assessing ileal Crohn's disease 663
Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: A single-center cohort study 644
Frequency, pattern, and risk factors of postoperative recurrence of Crohn's disease after resection different from ileo-colonic 625
Accuracy of small-intestine contrast ultrasonography, compared with computed tomography enteroclysis, in characterizing lesions in patients with Crohn's disease 625
Wireless capsule endoscopy and proximal small bowel lesions in Crohn's disease 612
Frequency and pattern of endoscopic recurrence in Crohn's disease patients with ileocolonic resection using a laparoscopic versus laparotomic approach: A prospective longitudinal study 574
Non-invasive techniques for assessing postoperative recurrence in Crohn's disease 537
Wireless capsule endoscopy and small intestine contrast ultrasonography in recurrence of Crohn's disease 521
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study 505
Severity of postoperative recurrence in Crohn's disease: Correlation between endoscopic and sonographic findings 469
Multiple Orocutaneous Extraintestinal Manifestations in Ulcerative Colitis Patient: Complete Response to Ustekinumab 400
Telemedicine in inflammatory bowel disease from its origin to the post pandemic golden age: A narrative review 388
Adherence to Mediterranean Diet and Diet Quality in Patients with Inflammatory Bowel Disease: A Single-Center, Observational, Case-Control Study 182
Italian validation of the IBD-disk tool for the assessment of disability in inflammatory bowel diseases: A cross-sectional multicenter study 147
Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus 139
Suboptimal disease control and contributing factors in Italian IBD patients: The IBD-PODCAST Study 108
Eosinophilic esophagitis in the "atopic march": dupilumab as an "umbrella" strategy for multiple coexisting atopic diseases 88
Patient Satisfaction with IBD Undergoing Colonoscopy: A Multicenter Cross-Sectional Study 72
Interplay Between Depression and Inflammatory Bowel Disease: Shared Pathogenetic Mechanisms and Reciprocal Therapeutic Impacts-A Comprehensive Review 66
Adaptation of the European Crohn's Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensus 60
Real-world Effectiveness of Tofacitinib on Ulcerative Colitis-Associated Spondyloarthropathy: a multicenter prospective study from the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD) 46
Corrigendum to "Telemedicine in inflammatory bowel disease from its origin to the post pandemic golden age: A narrative review" [Digestive and Liver Disease, Volume 56, Issue 1, January 2024, Pages 1-6] 38
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC) 34
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning—the IG-IBD LIVE study 33
IBD impact on quality of life and perception of disease activity in Italian patients and physicians: An IBD-PODCAST study sub analysis 29
Crohn’s disease and ulcerative colitis patient-reported outcomes signs and symptoms for the remote management of inflammatory bowel disease during the COVID-19 pandemic 13
Xanthine Oxidase-Dependent Activation of NLPR3 Inflammasome in Epithelial Cells Sustains Inflammation in Inflammatory Bowel Disease 8
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease 1
Totale 67.415
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.736
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 90.736
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.555 0 0 0 0 0 313 107 248 78 120 126 563
2021/20225.351 220 367 306 237 377 498 188 351 646 570 934 657
2022/20238.657 544 1.071 1.175 529 725 1.276 454 733 461 543 738 408
2023/20247.747 399 352 293 492 633 1.533 953 824 395 528 635 710
2024/202539.273 15.737 12.943 4.297 2.031 939 1.434 1.084 58 225 180 133 212
2025/20262.400 333 167 646 589 342 323 0 0 0 0 0 0
Totale 67.415